Join Growin Stock Community!

國鼎4132.TW Overview

TW StockBiotech. & Medical
(No presentation for 4132)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

國鼎（4132）Overall Performance

國鼎（4132）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

國鼎（4132） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

國鼎（4132）Key Information

國鼎（4132）Profile

Golden Biotechnology Corporation operates as a drug discovery and healthy food supplement manufacturing company in Taiwan, the United States, Japan, China, Korea, and Singapore. Its products include Liverty that is used for liver health support and fatigue; Rasle, an auto-immune adjuvant therapy; ZSAINO, a nourishment product for recovery from illness and for health improvement; and UMOOZE, a herbal formula for optimal health in males. The company also provides Antroquinonol, an anticancer molecule for the treatment of pancreatic cancer, acute myeloid leukemia, and hepatocellular carcinoma, as well as hypercholesterolemia and hyperlipidemia. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.

國鼎（4132）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.71
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
23.96
PB Ratio
13.58
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
4.51%
Net Margin
-626.39%
Revenue Growth (YoY)
-63.95%
Profit Growth (YoY)
-97.04%
3-Year Revenue Growth
-17.01%
3-Year Profit Growth
-22.92%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.71
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
23.96
PB Ratio
13.58
Price-to-FCF
-
Gross Margin
4.51%
Net Margin
-626.39%
Revenue Growth (YoY)
-63.95%
Profit Growth (YoY)
-97.04%
3-Year Revenue Growth
-17.01%
3-Year Profit Growth
-22.92%
default symbol

4132

國鼎

14.20D

-4.23%

(-0.04)

  • When is 4132's latest earnings report released?

    The most recent financial report for 國鼎 (4132) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4132's short-term business performance and financial health. For the latest updates on 4132's earnings releases, visit this page regularly.

  • How much cash does 4132 have?

    At the end of the period, 國鼎 (4132) held Total Cash and Cash Equivalents of 61.02M, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4132 go with three margins increasing?

    In the latest report, 國鼎 (4132) did not achieve the “three margins increasing” benchmark, with a gross margin of -6.15%%, operating margin of -407.12%%, and net margin of -432.18%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4132's profit trajectory and future growth potential.